期刊文献+

人黑色素瘤抗原MAGE-3基因的克隆与表达 被引量:7

Cloning and expressing of human melanoma antigen MAGE-3
下载PDF
导出
摘要 目的克隆人黑色素瘤特异抗原 MAGE- 3基因 ,以制备肿瘤 DNA疫苗。方法用 RT- PCR方法制备 MAGE-3基因 ,以哺乳细胞高效表达质粒 p CI- neo为载体 ,构建重组 DNA疫苗。重组体用载体上的通用引物为测序引物 ,鉴定克隆的正确性。再将鉴定过的重组质粒用脂质体法转化 2 93细胞 ,用免疫印迹法鉴定转化细胞中 MAGE- 3基因的表达。结果正确构建了 MAGE- 3/p CI- neo重组质粒 ,并且在转化细胞中检测出了 MAGE- 3的表达。结论成功地构建了重组 MAGE- 3/p CI- neo肿瘤核酸疫苗 。 ObjectiveTo clone human melanoma antigen MAGE 3 gene to produce tumor DNA vaccine Methods Recombinant DNA vaccine was constructed by ligating MAGE 3 gene, which was prepared by RT PCR and the vector pCI neo that can express in mammals with high efficiency The recombinant was sequenced on an automatic sequencer with T7 promoter and T3 promoter sequence as sequencing primers that locate upstream and downstream of the multiple cloning site (MCS) respectively and the correctness of recombinant was determined The identified recombinant plasmids were then transformed into 293 cells with liposome, the expression of MAGE 3 was checked by western blot ResultsThe recombinant MAGE 3/pCI neo plasmid had been constructed correctly and the expression of MAGE 3 gene in transformed 293 cells had been determined ConclusionWe had constructed successfully the recombinant MAGE 3/pCI neo tumor vaccine Its anti tumor effects could be observed further in animal models
出处 《免疫学杂志》 CAS CSCD 北大核心 2001年第6期406-409,共4页 Immunological Journal
基金 国家自然科学基金资助项目 (3990 0 134)
  • 相关文献

参考文献4

  • 1Gurunathan S,Current Opinion Immunol,2000年,12卷,4期,442页
  • 2Leitner W W,Vaccines,2000年,18卷,9/10期,765页
  • 3贾正才,国外医学.肿瘤学分册,2000年,27卷,增刊,42页
  • 4Weber J S,J Immunother,1999年,22卷,5期,431页

同被引文献54

  • 1朱波,陈正堂,程晓明,吴玉章.泰素耐药相关基因-3细胞毒性T淋巴细胞表位负载树突状细胞疫苗的体外免疫效应研究[J].中华肿瘤杂志,2004,26(12):709-712. 被引量:3
  • 2董薇,蔡美英.树突状细胞和T细胞相互作用过程中的免疫突触[J].细胞与分子免疫学杂志,2005,21(B03):13-16. 被引量:2
  • 3金冬雁 黎孟枫.分子克隆实验指南(第2版)[M].北京:科学出版社,1996.867-897.
  • 4[1]Srivastava IK, Liu MA. Gene vaccines [ J ]. Ann Intern Med, 2003, 138 (7): 550-559.
  • 5[2]Hanke T, BarnfieldC, Wee EG, et al. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine [J]. J Gen Virol, 2003, 84 (Pt 2): 361 - 368.
  • 6[3]Ilan E, Eren R, Lubin I, et al. The Trimera mouse: a system for generating human monoclonal antibodies and modeling human diseases [J]. Curr Opin Mol Ther, 2002, 4 (2):102- 109.
  • 7[6]Ilan E , Arazi J , Nussbaum O , et al . The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV [J]. J Infect Dis, 2002, 185 (2): 153 - 161.
  • 8[8]Scheibenbogen C, Romero P, Rivoltini L, et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNgammaELISPOT assay and chromium-release assay: a four-centre comparative trial [J]. J Immunol Methods, 2000, 244(1/2):81 - 89.
  • 9[9]Mosier DE. Adoptive transfer of human lymphoid cells to severely immunodeficient mice: models for normal human immune function, autoimmunity, lymphomagenesis, and AIDS [J]. Adv Immunol, 1991, 50:303 - 325.
  • 10[10]Okano M, Taguchi Y, Nakamine H, et al. Characterization of Epstein-Barr virus-induced lymphoproliferation derived from human peripheral blood mononuclear cells transferred to severe combined immunodeficient mice [ J ]. Am J Pathol, 1990,137 (3): 517 - 522.

引证文献7

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部